Wednesday, May 5, 2021

Advertising

Home General News Pfizer eyes $34b in COVID-19 sales in 2021, sees demand lasting for...

Pfizer eyes $34b in COVID-19 sales in 2021, sees demand lasting for years


Next-generation shot

Mr Bourla said Pfizer is testing a third dose of the existing formulation of its COVID shot to determine whether a booster provides protection against SARS-CoV-2 virus variants currently in circulation.

The company has begun evaluating an updated formulation that encodes the spike protein of the variant first identified in South Africa. “This study is designed to establish a regulatory pathway to update the current vaccine to address any future variant of potential…



Click here to view the original article.

- Advertisment -
- Advertisment -

Recently Viewed

You might also like ...

Hotspotting: QLD regions top national ‘best buys’ of 2021 list
Minister’s warning over electric car tax